Cargando…

Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk

INTRODUCTION: Vitamin D receptor (VDR) genotypes may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D, but epidemiological studies have been inconsistent. Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Sascha, Nieters, Alexandra, Linseisen, Jakob, Slanger, Tracy, Kropp, Silke, Mutschelknauss, Elke Jonny, Flesch-Janys, Dieter, Chang-Claude, Jenny
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397533/
https://www.ncbi.nlm.nih.gov/pubmed/18419802
http://dx.doi.org/10.1186/bcr1994
_version_ 1782155637674737664
author Abbas, Sascha
Nieters, Alexandra
Linseisen, Jakob
Slanger, Tracy
Kropp, Silke
Mutschelknauss, Elke Jonny
Flesch-Janys, Dieter
Chang-Claude, Jenny
author_facet Abbas, Sascha
Nieters, Alexandra
Linseisen, Jakob
Slanger, Tracy
Kropp, Silke
Mutschelknauss, Elke Jonny
Flesch-Janys, Dieter
Chang-Claude, Jenny
author_sort Abbas, Sascha
collection PubMed
description INTRODUCTION: Vitamin D receptor (VDR) genotypes may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D, but epidemiological studies have been inconsistent. Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans, has rarely been examined. METHODS: We assessed the effects of two frequently analyzed polymorphisms (FokI and TaqI) and two potentially functional variants (VDR-5132 and Cdx2) in the VDR gene, which thus far have not been analyzed with respect to breast cancer risk, on postmenopausal breast cancer risk in a population-based, case-control study including 1,408 patients (cases) and 2,612 control individuals (controls) matched for year of birth. Odds ratios (ORs) for breast cancer adjusted for potential confounders were calculated for genotypes and estimated haplotypes. RESULTS: No differences in serum 25(OD)D concentrations by VDR genotype were observed. None of the analyzed polymorphisms was associated with overall risk for postmenopausal breast cancer. However, the TaqI polymorphism was associated with a significantly increased risk for oestrogen receptor positive tumours (OR = 1.18, 95% confidence interval [CI] = 1.00 to 1.38, comparing t allele carriers with noncarriers) but not for oestrogen receptor negative tumours (OR = 0.88, 95% CI = 0.69 to 1.13; P for interaction = 0.04). Haplotype analysis revealed the haplotype FtCA (FokI F, TaqI t, VDR-5132 C, Cdx2 A), which contains the TaqI t allele, to be associated with a significantly greater breast cancer risk as compared with the most frequent haplotype FTCG (OR = 1.43, 95% CI = 1.00 to 2.05). No significant interaction between VDR genotypes or haplotypes and 25(OH)D was observed. CONCLUSION: Our results support potential effects of VDR polymorphisms on postmenopausal breast cancer risk and possible differential effects of receptor status of the tumour. However, further studies focusing on the influence of polymorphisms and haplotypes on VDR functionality, activity and concentration are needed.
format Text
id pubmed-2397533
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-23975332008-05-30 Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk Abbas, Sascha Nieters, Alexandra Linseisen, Jakob Slanger, Tracy Kropp, Silke Mutschelknauss, Elke Jonny Flesch-Janys, Dieter Chang-Claude, Jenny Breast Cancer Res Research Article INTRODUCTION: Vitamin D receptor (VDR) genotypes may influence breast cancer risk by altering potential anticarcinogenic effects of vitamin D, but epidemiological studies have been inconsistent. Effect modification by serum 25-hydroxyvitamin D (25 [OH]D), the biomarker for vitamin D status in humans, has rarely been examined. METHODS: We assessed the effects of two frequently analyzed polymorphisms (FokI and TaqI) and two potentially functional variants (VDR-5132 and Cdx2) in the VDR gene, which thus far have not been analyzed with respect to breast cancer risk, on postmenopausal breast cancer risk in a population-based, case-control study including 1,408 patients (cases) and 2,612 control individuals (controls) matched for year of birth. Odds ratios (ORs) for breast cancer adjusted for potential confounders were calculated for genotypes and estimated haplotypes. RESULTS: No differences in serum 25(OD)D concentrations by VDR genotype were observed. None of the analyzed polymorphisms was associated with overall risk for postmenopausal breast cancer. However, the TaqI polymorphism was associated with a significantly increased risk for oestrogen receptor positive tumours (OR = 1.18, 95% confidence interval [CI] = 1.00 to 1.38, comparing t allele carriers with noncarriers) but not for oestrogen receptor negative tumours (OR = 0.88, 95% CI = 0.69 to 1.13; P for interaction = 0.04). Haplotype analysis revealed the haplotype FtCA (FokI F, TaqI t, VDR-5132 C, Cdx2 A), which contains the TaqI t allele, to be associated with a significantly greater breast cancer risk as compared with the most frequent haplotype FTCG (OR = 1.43, 95% CI = 1.00 to 2.05). No significant interaction between VDR genotypes or haplotypes and 25(OH)D was observed. CONCLUSION: Our results support potential effects of VDR polymorphisms on postmenopausal breast cancer risk and possible differential effects of receptor status of the tumour. However, further studies focusing on the influence of polymorphisms and haplotypes on VDR functionality, activity and concentration are needed. BioMed Central 2008 2008-04-17 /pmc/articles/PMC2397533/ /pubmed/18419802 http://dx.doi.org/10.1186/bcr1994 Text en Copyright © 2008 Abbas et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Abbas, Sascha
Nieters, Alexandra
Linseisen, Jakob
Slanger, Tracy
Kropp, Silke
Mutschelknauss, Elke Jonny
Flesch-Janys, Dieter
Chang-Claude, Jenny
Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title_full Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title_fullStr Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title_full_unstemmed Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title_short Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
title_sort vitamin d receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2397533/
https://www.ncbi.nlm.nih.gov/pubmed/18419802
http://dx.doi.org/10.1186/bcr1994
work_keys_str_mv AT abbassascha vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT nietersalexandra vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT linseisenjakob vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT slangertracy vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT kroppsilke vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT mutschelknausselkejonny vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT fleschjanysdieter vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk
AT changclaudejenny vitamindreceptorgenepolymorphismsandhaplotypesandpostmenopausalbreastcancerrisk